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Abstract The serotonin (5-HT) transporter (SERT) plays
an important role in the termination of 5-HT-mediated
neurotransmission by transporting 5-HT away from the
synaptic cleft and into the presynaptic neuron. In addition,
SERT is the main target for antidepressant drugs, including
the selective serotonin reuptake inhibitors (SSRIs). The
three-dimensional (3D) structure of SERT has not yet been
determined, and little is known about the molecular
mechanisms of substrate binding and transport, though
such information is very important for the development of
new antidepressant drugs. In this study, a homology model
of SERT was constructed based on the 3D structure of a
prokaryotic homologous leucine transporter (LeuT) (PDB
id: 2A65). Eleven tryptamine derivates (including 5-HT)
and the SSRI (S)-citalopram were docked into the putative
substrate binding site, and two possible binding modes of
the ligands were found. To study the conformational effect
that ligand binding may have on SERT, two SERT–5-HT
and two SERT–(S)-citalopram complexes, as well as the
SERT apo structure, were embedded in POPC lipid bilayers
and comparative molecular dynamics (MD) simulations
were performed. Our results show that 5-HT in the SERT–
5-HT
B complex induced larger conformational changes in
the cytoplasmic parts of the transmembrane helices of
SERT than any of the other ligands. Based on these results,
we suggest that the formation and breakage of ionic
interactions with amino acids in transmembrane helices 6
and 8 and intracellular loop 1 may be of importance for
substrate translocation.
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Introduction
The serotonin [5-hydroxytryptamine (5-HT)] transporter
(SERT) is located in the membrane of presynaptic
neurons and plays an important role in the termination
of serotonergic neurotransmission by transporting 5-HT
from the synaptic cleft into the presynaptic neuron. SERT,
and the closely related dopamine and noradrenaline (norepi-
nephrine) transporters (DAT and NET, respectively), are
located in limbic areas of the CNS that are involved in mood,
emotion and reward processes, and are important targets of
therapeutic drugs aswell aspsychoactiveillicit drugs.Among
the compounds that act on SERT are drugs belonging to the
two main groups of antidepressants—the classic tricyclic
antidepressants (TCAs) and the newer selective serotonin
reuptake inhibitors (SSRIs)—and well-known drugs of abuse
such as cocaine and amphetamines, including 3,4-methylene-
dioxy-N-methamphetamine (MDMA, commonly known as
“ecstasy”).
SERT, DAT and NET belong to the neurotransmitter/
sodium symporter (NSS) transporter family (Transporter
Classification code 2.A.22 [1]), also known as the SLC6
family [2]. This transporter family constitutes a large
number of secondary transporters that use Na
+ electro-
chemical gradients to transport extracellular solutes across
membranes. At least 177 eukaryotic and 167 prokaryotic
transporters have been classified as belonging to this family
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DOI 10.1007/s00894-011-1133-1[3], transporting a large number of solutes. In addition to
the biogenic amines, amino acids such as γ-aminobutyric
acid (GABA), glycine, tryptophan, tyrosine and leucine
(the GAT-1, GlyT, TnT, Tyt1 and LeuT transporters,
respectively) are transported by NSS transporters [1].
The three-dimensional (3D) structure of SERT (or, indeed,
that of any eukaryotic NSS family member) has not been
experimentally determined; however, the first X-ray crystal
structure of a prokaryotic NSS family member, the Aquifex
aeolicus leucine transporter (LeuT), was published in 2005
[4]. Since then, several crystal structures of LeuT have been
published, and 3D structures of LeuT in an occluded
conformation [5–7] and in an outward-facing conformation
[8] are now available. These crystal structures can be used as
templates for the generation of 3D models of SERTand other
NSS transporters using the homology modeling approach,
taking advantage of the fact that 3D structure is more
conserved than the sequence [9]. Several SERT models have
been generated based on the occluded LeuT crystal structure
[10–12] and a published comprehensive alignment of NSS
family members by Beuming et al. [3].
In 1966, transporter proteins were suggested to operate
through an alternating-access mechanism [13] in which a
central substrate binding site is alternately exposed to either
the extracellular environment or the cytoplasm through
conformational changes of the protein. The 3D crystal
structures of LeuT thus fit this proposed transport mecha-
nism, as they are in open-to-out and occluded conforma-
tions [4–8]. In the latter conformation, leucine is bound in
the substrate binding site of LeuT, and the side chains of
two phenylalanine residues (corresponding to Y176 and
F335 in SERT) and one arginine and glutamate residue
(corresponding to R104 and E493 in SERT) block access
from the extracellular environment to the substrate binding
site [4–7]. In the outward-facing conformation, the com-
petitive inhibitor L-tryptophan displaces leucine from the
substrate binding site and causes LeuT to stabilize in an
outward-facing conformation, where the distance between
the side chains of Y176 and F335 increases [8]. In all of the
LeuT 3D structures, however, approximately 20 Å of
tightly packed helical regions effectively separate the
substrate binding site from the cytoplasmic environment
[4–8]. Thus, neither the crystal structures of LeuT nor the
SERT homology models based on these structures reveal
much information about how substrates are transported
from the extracellular environment into the interiors of the
cells. One possible way to gain more insight into the
conformational mechanisms that take place in a transporter
following the binding of either substrate or inhibitor may be
by performing long molecular dynamics (MD) simulations.
To study ligand binding and SERT conformational
changes upon ligand binding, the LeuT occluded structure
(PDB id 2A65) [4] was used to generate a homology model
of SERT, and 5-HT and ten other tryptamine derivatives, as
well as the SSRI (S)-citalopram, were docked into the
putative substrate binding pocket detected in the SERT
model. Analysis of the docking results revealed two
putative binding modes of the tryptamine derivatives and
(S)-citalopram in SERT. Based on these docking results, one
representative complex of SERT and 5-HT and (S)-citalo-
pram in both binding modes was selected for MD
simulations, in addition to the apo-SERT. The MD
simulations were performed after embedding the SERT–
ligand complexes in palmitoyloleoyl-phosphatidylcholine
(POPC) lipid bilayers. The results from the MD simulations
of the five SERT–(ligand)–POPC complexes showed that
the putative substrate binding site had started to extend
towards the intracellular parts of SERT during the MD
simulation in one of the SERT–5-HT complexes (namely,
the SERT–5-HT
B complex). In the same complex, a
vestibule extending from the cytoplasm towards the
substrate binding site had started to form. Based on these
results, we identified several amino acids that may play a
role in the opening and closing of a vestibule reaching from
the substrate binding site to the cytoplasm.
Methods
Homology modeling of SERT
The SERT (UniProtKB/Swiss-Prot accession number
P31645 [14]) and the LeuT (PDB id 2A65) [4] amino acid
sequences were aligned using ICM software (version 3.5)
[15], and the alignment was adjusted to fit the published
comprehensive alignment of NSS family members [3].
Based on this alignment, the homology model of SERT was
constructed using the BuildModel macro of ICM [15]. The
macro constructs the backbone of the target protein using
the backbone conformation of the template in the aligned
regions using core sections defined by the average Cα atom
positions in these regions. The conformations of the side
chains of amino acids that were identical for the template
and the target structures were then transferred from the
template to the target, whereas nonidentical side chains
were assigned their most likely rotamer. For the loops with
insertions or deletions between the template and target
sequences, the macro performs a loop search of the PDB
database, selecting loops with matching loop ends and a
loop sequence that is as closed as possible. The loops are
inserted into the model and the side chains are modified
according to the model sequence and steric interactions
with the surroundings of the model.
The SERT amino acids E78-T192 and W220-I608 were
included in the homology model. These amino acids comprise
the 12 putative transmembrane helices (TMs) and the
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connecting the transmembrane helices, except for parts of
the large EL2 (amino acids 193–219). This loop segment
was not included in the model as it is lacking in the
LeuT template. Amino acids corresponding to the N-
terminal (amino acids 1–77) and C-terminal (amino acids
609–630) regions of SERT were also not included in the
model for the same reason.
The two sodium ion binding sites and one chloride
binding site in the LeuT crystal structure [4] were copied to
SERTafter superimposing the LeuTcrystal structure and the
SERT model. A chloride ion was also added to the SERT
homology model such that it occupied a position
corresponding to the carboxylate carbon coordinates of
LeuT glutamic acid at position 290 (corresponding to S372
in SERT), as suggested by Forrest [11] and Zomot [16].
Energy refinement of the SERT homology model was
performed using the ICM RefineModel macro. This three-
step macro performs (1) a side-chain conformational
sampling using “Montecarlo fast” [17], (2) iterative
annealing with tethers provided, and (3) a second side-
chain sampling. The program module Montecarlo fast [17]
samples the conformational space by performing iterations
that consist of a random move followed by a local energy
minimization. The complete energy is then calculated, and
the iteration is accepted or rejected based on the energy and
the temperature. In the annealing of the backbone (step 2),
the tethers included are harmonic restraints that pull an
atom in the model to a static point in space represented by a
corresponding atom in the template.
The energy-refined SERT homology model was
uploaded to the SAVES server for a structure quality check
(http://nihserver.mbi.ucla.edu/Saves_3/). The Ramachan-
dran plot provided by Procheck showed that the SERT
homology model was a good-quality model; 96.6% of the
non-glycine and non-proline amino acids were in the
favored regions, whereas 3.4% (12 amino acids) were in
additional allowed regions. Of these 12 amino acids, one
amino acid, D98, was located in the putative substrate
binding area. This amino acid is important for substrate
and inhibitor binding to SERT [10, 12, 18–20], and was
located in an unwound region of TM1. However, this
location gives D98 more freedom to rotate, and hence
explains its location in additionally allowed regions of the
Ramachandran plot.
Ligand docking
To detect possible binding pockets in the SERT structure,
the ICM PocketFinder macro was used (default tolerance
level of 4.6). The algorithm uses a transformation of the
Lennard–Jones potential calculated from a three-dimensional
protein structure and does not require any knowledge about a
potential ligand molecule; i.e., it is based solely on protein
structure [21].
5-HT and ten other tryptamine derivatives (tryptamine,
4-hydroxytryptamine (4-HT), 7-methyltryptamine (7-MT),
2-methylserotonin (2-MT), 5-methoxy-3-(1,2,5,6-tetrahy-
dro-4-pyridinyl)-1 H-indole (RU24969), N-isopropyltrypt-
amine (NIT), 5-methoxy-N-isopropyltryptamine (5MNIT),
7-benzyloxytryptamine (7-BT), 5,6,7-trihydroxytryptamine
and serotonin o-sulfate (Table 1) were constructed using the
ChemDraw option of ICM. Default ECEPP/3 partial
charges were assigned to the protonated forms of the
ligands [22], and the compounds were docked using the
batch docking method of ICM. RU24969 was also docked in
its unprotonated state. The SSRI [(S)-1-[3-(dimethylamino)
propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5 car-
bonitrile; (S)-citalopram] (Table 1) was constructed using
ChemDraw and docked into the same binding site as the
tryptamine derivatives, as experimental studies indicate that
(S)-citalopram is a competitive 5-HT inhibitor [18]. The
ligands were docked using a semi-flexible docking protocol
where SERT was kept rigid but the ligands flexible.
The poses of each ligand were clustered and compared
with the clusters of the other ligands. This analysis led to
the identification of two putative ligand positions for
both the tryptamine derivatives and (S)-citalopram. One
representative from each of the two clusters of 5-HT
(representing the tryptamine derivatives) and (S)-citalopram
were selected for MD simulations.
Molecular dynamics simulation
The automated CHARMM-GUI membrane builder tool
[23] was used for the generation of a palmitoyloleoylphos-
phatidylcholine (POPC) lipid bilayer around the five
SERT–(ligand) complexes selected after docking. The pre-
orientated LeuT structure [4] from the Orientations of
Proteins in Membranes (OPM) database [24] was used to
orient the SERT model in the membrane by superimposing
the LeuT and SERT. An unequilibrated lipid bilayer was
generated using the replacement method, in which SERT
was packed with lipid-like spheres whose positions then
were used to place randomly chosen POPC lipid
molecules from a lipid library composed of 2000
different conformations of lipids generated by MD
simulations of pure lipid bilayers. The dimensions of
the entire SERT–(ligand)–POPC molecular system was
approximately 100×100×100 Å, including 1 Å extra
added in each direction in order to introduce space
between the boundary of the system and the boundary
atoms of the simulation cell. One hundred fifteen lipids
were included in the outer bilayer and 121 in the inner
bilayer. Water molecules (TIP3) and K
+ and Cl
− ions
were then added by the membrane builder tool to fully
J Mol Model (2012) 18:1073–1085 1075solvate the system. In total, each of the five complexes
consisted of approximately 98,000 atoms.
The NAMDscalable MDsimulator (versions2.6and2.7b1)
[25] was used to equilibrate the systems and perform
the production runs. The MD simulations were run
u s i n g6 4p r o c e s s o r so nt h eS tallo supercomputer at the
University of Tromsø, Norway, using Chemistry at HARvard
Molecular Mechanics (CHARMM) force fields. The
CHARMM par_all27_prot_lipidNBFIX parameter file,
which includes the CHARMM22/CMAP force field [26, 27]
for the protein and the CHARMM27 force field [28, 29]f o r
lipids, was used. For the complexes containing 5-HT or (S)-
citalopram, the CHARMM36 general force field for small
molecule drug design (CGenFF v. 2a3 [30]) was included,
manually adding force field angle and dihedral parameters
that are not included in CGenFF v. 2a3 [30]. To allow the
large volume fluctuations that are typical of the initial
dynamics of a new system in an NPT ensemble, a margin of
5 was used during the equilibration steps, which was reduced
to 2 during the production runs [25]. During the simulations,
Table 1 The structures of tryptamine derivatives and (S)-citalopram docked into the putative substrate binding site in SERT. Positions of
substitutions in the tryptamine derivatives are shown
1076 J Mol Model (2012) 18:1073–1085Nosé–Hoover–Langevin dynamics were used to simulate the
NPT ensemble. This method combines the Nosé–Hoover
constant pressure method with piston fluctuation control
implemented using Langevin dynamics by coupling the
piston to a heat bath. A damping constant of 10/
langevinPistonDecay was used during the equilibration
steps, which was reduced to 1/langevinPistonDecay
during the production runs. The langevinPistonDecay
(50 fs) was set to be smaller than langevinPistonPeriod
(200 fs) to ensure that harmonic oscillations in the
periodic cell were overdamped. The target pressure was
set at 1.01325 bar (atmospheric pressure at sea level), and
group-based pressure (useGroupPressure) was used to control
the periodic cell fluctuations, as the atom-based pressure has
more high-frequency noise. In addition, a flexible cell
(useFlexibleCell) was used, allowing the height, length, and
width of the cell to fluctuate independently during the
simulation, which is very useful for anisotropic systems such
as membranes.
The equilibration of the five SERT–(ligand)–POPC
complexes consisted of three steps during which the system
was gradually released. During steps (1) and (2), harmonic
constraints of 1 kcal mol
−1 Å
−2 were specified in the PDB
beta field of each atom to be constrained. In order to induce
the appropriate order of the fluid-like bilayer, all atoms
except the lipid tail atoms were constrained during step (1),
and lipids, water and ions were permitted to adapt to the
structure of the protein. During step (2), only protein atoms
were constrained, whereas the whole system was released
during step (3). During step (1), 10,000 steps of conjugate
gradient energy minimization were performed, followed by
10,000 steps (10 ps) of system heating to 300 K under
constant temperature control and 500,000 steps (0.5 ns) of
MD. During steps (2) and (3), only 10,000 steps of
conjugate gradient minimization followed by 500,000 steps
(0.5 ns) of MD were performed. In total, 30,000 steps of
conjugate gradient minimization, 10 ps of heating and
1.5 ns of MD simulations were run to equilibrate the
system. To confirm that the systems stabilized during
equilibration, the RMSD from the starting structure was
monitored during each simulation using the molecular
dynamics (VMD) viewer version 1.8.6 [31]. Finally, the
equilibration phases of the SERT–5-HT binding modes A
and B and the (S)-citalopram binding modes A and B, as
well as SERT alone, were followed by 22, 21, 32, 23 and
25 ns MD simulations, respectively. The production
simulations were performed at 300 K. Following the
production runs, VMD [31] was used to generate average
structures of each complex based on the last 10 ns of each
simulation, and ICM PocketFinder [21] was used to detect
possible pockets in the average structures. Based on the
these analyses, the SERT–5-HT
B complex MD simulation
was prolonged to 49 ns.
Results
Homology modeling
The constructed homology model consisted of 12 TMs,
among which TMs 1–5 and 6–10 were arranged with a
pseudo-twofold axis in the membrane plane, as for LeuT
[4]. Three possible binding pockets were identified by
ICM PocketFinder in the SERT homology model: one in
the region corresponding to the LeuT substrate binding
site, and two extracellular pockets which were separated
from the putative substrate binding pocket by the side
chains of Y176 and F335, the aromatic amino acids of the
extracellular gate. In LeuT [4], only one pocket was
detected in this extracellular region, as EL4 in LeuT is
missing three amino acids at the tip of EL4 as compared to
SERT [3] (results not shown).
ICM PocketFinder [21] identified a binding pocket
that corresponded to the substrate binding site of LeuT
[4]. Experimental data on SERT and the X-ray structure
of LeuT also suggest that the substrate binding site of
SERT and LeuT are in the same region [10, 12, 20, 32–
34], halfway across the membrane bilayer within the
TMs. This location is also consisted with the alternate
access theory [13]. Amino acids from four TMs
contribute to the binding pocket detected by ICM
PocketFinder, namely from TM1 (Y95, D98, G100),
TM3 (I172, A173, Y176), TM6 (F335, S336, G338,
F341, V343) and TM8 (S438, T439, G442). An
important feature of the detected binding pocket is the
deviation from regular helical structure in the unwound
regions of TM1 (A96–D98) and TM6 (G338–G342). A
similar deviation is observed in corresponding regions
of the X-ray structure of LeuT. In the unwound regions,
the main-chain carbonyl oxygen and amide nitrogen
atoms are exposed such that they can easily take part in
direct hydrogen-bonding interactions with ligands and
coordinate ions.
The substrate binding pocket detected by ICM Pocket-
Finder could be divided into three subpockets based on
the main properties of amino acids involved. The first
subpocket, the hydrophobic subpocket, was located
towards the intracellular end of the binding site and
was surrounded by the side chains of A169 (TM3), A173
(TM3), V343 (TM6), and G442 (TM8). The side chain
of I172 (TM3) was positioned such that it could participate
in forming the hydrophobic subpocket but also separate the
hydrophobic subpocket from an aromatic. The aromatic
subpocket consisted of the side chains of the two aromatic
amino acids of the extracellular gate, Y176 (TM3) and
F335,andF341locatedin theunwoundregionofTM6.The
third subpocket, the ionic subpocket, was located in the
vicinity of D98 (TM1).
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The docking of 5-HT and ten other tryptamine derivatives
and (S)-citalopram indicated two possible binding modes of
the compounds, designated SERT–5-HT
A, SERT–5-HT
B,
SERT–(S)-citalopram
A and SERT–(S)-citalopram
B, respec-
tively (Fig. 1). The SERT–5-HT binding modes represent
the binding poses of all tryptamine derivatives. In both the
SERT–5-HT
A and SERT–5-HT
B binding modes, 5-HT
occupied the ionic and hydrophobic—but not the aromat-
ic—subpockets of the binding site. The protonated amine
of 5-HT was located near the D98 carboxyl side chain in
both modes, which is in accordance with experimental
data [10, 12, 19, 20]. The two binding modes of 5-HT
differ in the orientation of the indole ring nitrogen and the
orientation of the 5 position (Fig. 1). In the SERT–5-HT
A
binding mode, the indole ring nitrogen was found between
Y95 and F341, whereas the 5 position was pointing
towards Y176, S438 and T439. In the SERT–5-HT
B
binding mode, however, the indole ring was flipped 180°
compared to binding mode A, and the indole nitrogen
group was pointing towards the aromatic side chains of
Y176 and S438, and the 5 position towards A169 and
F341 (Fig. 1). Interestingly, similar binding modes of 5-
HT to the SERT–5-HT
A and SERT–5-HT
B binding modes
have also been described by other groups [10, 12, 35].
Fig. 1 Ligand binding modes detected through docking. a SERT–5-
HT
A binding mode, b SERT–5-HT
B binding mode, c SERT–(S)-
citalopram
A binding mode, and d SERT–(S)-citalopram
B binding mode.
The side chains of amino acids Y95, D98 and I172 and the binding
pocket detected by ICM PocketFinder (red wire representation)a r e
shown. Color coding of atoms in amino acids: red oxygen, blue
nitrogen, gray carbon and hydrogen. Color coding of ligands: red
oxygen, blue nitrogen, yellow carbon, gray hydrogen
1078 J Mol Model (2012) 18:1073–1085Predictions of the 5-HT–SERT binding energies for the two
binding modes using the calcBindingEnergy macro of ICM
[36] showed that the poses represented by the SERT–5-
HT
A complex had binding energies in the range −5.7 to
−13.8 kcal mol
−1 (average −10.0 kcal mol
−1), while poses
represented by the SERT–5-HT
B complex had binding
energies in the range −4.8 to −10.7 kcal mol
−1 (average
−8.1 kcal mol
−1).
In the SERT–(S)-citalopram
A binding mode (Fig. 1), (S)-
citalopram occupied all three subpockets of the putative
substrate binding site. The amine moiety of (S)-citalopram
was located in the ionic subpocket close to D98, whereas
the cyanophthalane and fluorophenyl moieties were located
in the hydrophobic (in close proximity to A169, A173,
V343 and G442) and aromatic subpockets (pointing
towards F335), respectively. The oxygen moiety of (S)-
citalopram was pointing in the direction of Y95 (Fig. 1). In
comparison, the cyanophthalane and amine moieties of (S)-
citalopram in the SERT–(S)-citalopram
B binding mode
were also found in the hydrophobic and ionic subpockets,
respectively, in a very similar location to that in the SERT–
(S)-citalopram
A binding mode. However, the fluorophenyl
moiety of (S)-citalopram in this binding mode was found to
be juxtaposed in-between the side chains of Y95 and S438,
and the oxygen moiety was pointing in the direction of
Y176 (Fig. 1). The prediction of binding energies using the
calcBindingEnergy macro of ICM [36] showed that poses
represented by the SERT–(S)-citalopram
A complex had
binding energies in the range −7.4 to −19.1 kcal mol
−1
(average −14.7 kcal mol
−1), while those represented by the
SERT–(S)-citalopram
B complex had binding energies in the
range −12.7 to −19.7 kcal mol
−1 (average −16.4 kcal mol
−1).
Molecular dynamics simulations
In order to study possible conformational changes of SERT
upon the binding of 5-HT (substrate) and (S)-citalopram
(inhibitor), more than 20 ns of MD simulations were
performed for each system: one representative SERT–ligand
complex from each of the binding modes detected as well
as apo-SERT were embedded in POPC lipid bilayers,
followed by system equilibration and longer MD simula-
tions. The average structures of each of the five complexes
were then generated based on the last 10 ns of the production
runs, and ICM PocketFinder was used to detect possible
pockets that had formed in SERT during the production runs.
Interestingly, in the average structure of the SERT–5-HT
B
binding mode, the substrate binding pocket began to
elongate towards the cytoplasm, and another pocket started
to form that extended from the cytoplasm up towards the
elongated substrate binding pocket during the MD simula-
tion (Fig. 2). Our results showed that in the average structure
of SERT–5-HT
B, only a narrow stretch of TMs 6 and 8, in
additionto intracellular loop 1 (IL1),separatedthetwo pockets
and prevented access from the substrate binding site to
cytoplasm (Fig. 3). The other simulations also changed the
size of the substrate binding site and induced other pockets to
form; however, intracellular vestibules similar to that gener-
ated in the SERT–5-HT
B complex were not observed in any
of the other average structures (results not shown). Based on
these observations, the simulation of the SERT–5-HT
B
complex was prolonged to 49 ns. The prolongation indicated
that the pocket extending from the cytoplasm up towards the
elongated substrate binding pocket was also maintained
during 21 to 49 ns of the MD simulation.
Fig. 2 SERTstructures. a Initial
SERT structure and b the
average SERT–5-HT
B structure
generated based on the last
10 ns of the MD simulation.
“Intra-structural” pockets
detected by ICM PocketFinder
are shown. The putative
substrate binding pocket is
represented as red wire
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B structure (12–21 ns)
was slightly shifted compared with the initial structure
(Fig. 4). Superimposition of the structure of SERT prior to
MD and the average structure of the SERT–5-HT
B complex
showed that the hydroxyl oxygen atom of 5-HT was located
closer to the Y95 (TM1) hydroxyl group. The distance before
MD was 4.1 Å, while the distance in the average structure
was 3.4 Å (range 1.9–5.5 Å). 5-HT was also located 1.7 Å
closer to the cytoplasmic side than before MD. The distance
between the G338 (TM6) backbone oxygen and the Y95
(TM1) hydroxyl group also increased slightly, from 1.8 Å to
2.1 Å in the average structure (range 2.0–3.0 Å), indicating
that TMs 1 and 6 had begun to move further apart as well
(Fig. 4). Prolongation of the MD indicated that these distances
did not change much during 21–49 ns of MD. The distance
between the 5-HT hydroxyl group and the hydroxyl group of
Y95 varied between 2.3 and 5.3 Å, while the distance
between the G388 backbone oxygen and the Y95 hydroxyl
group varied between 1.8 and 2.7 Å.
The observation that only some residues block the access
from the putative substrate binding site to the cytoplasm
prompted us to look for amino acids in the unwound region
of TM6, in TM8, and in IL1 of SERT that may have
interacted with amino acids in other regions of SERT and
contributed to the formation of the emerging vestibule.
W ef o u n dG 3 4 0i nT M 6a n dE 4 4 4 ,D 4 5 2a n dE 4 5 3i n
TM8, as well as R152 and K153 in IL1 very interesting
1.8
1.7
2.1
3.4
4.1
1.7
Fig. 4 Comparison of the 5-HT binding mode in the initial SERT–5-
HT
B complex (gray) and that in the average SERT–5-HT
B structure
generated based on the last 10 ns of MD (orange). Atomic distances
(Å) are shown as dotted lines. For clarity, selected hydroxyl oxygen
atoms on 5-HT, Y95 and G338 are colored red
Fig. 3 a Intracellular view of the average SERT–5-HT
B structure.
SERT Cα carbon atoms are shown in gray cylindrical representation.
For clarity, amino acids 148–160, 338–350 and 444–453 are shown in
blue. The putative substrate binding site is displayed as red wire.
Amino acids that are proposed to play a role in the opening of a
vestibule extending from the putative substrate binding site (red wire
representation) to the cytoplasm are shown as xstick. b Close-up of a
with residues in xstick. Green lines show interactions formed during
the simulation; red line shows an interaction broken during simulation
1080 J Mol Model (2012) 18:1073–1085in this respect. The distances between these residues and
their interaction partners in the structure of SERT before
the MD simulations and in the average structures
generated following the MD simulations were thus measured
and compared (Table 2).
We also noted that the cytoplasmic part of TM3
(K159–I168) had unwound during the MD simulation
and had thus become more flexible. The unwinding may
have played a role in the opening of the vestibule;
however, this unwinding was seen in all average
structures and may be an artifact of poor force field
representation of protein–protein, protein–solvent and
solvent–lipid interactions. Using CHARMM force fields
and NPT for simulations in a tensionless ensemble may
lead to the condensation of the bilayer to a near gel-like
state, which may influence the protein structure and
result in incorrect predictions if the lateral density of
lipids increases beyond a liquid crystalline state [37]. The
unwinding may also be a result of structural differences
between SERT and LeuT in this region [3].
Structural differences between SERTand LeuTin IL1 may
explain the unwinding of the α-helical structure in IL1 that
waspresentintheinitialstructureofSERT,justasinLeuT[4],
but not in any of the average structures generated following
the MD simulations. The homology between SERTand LeuT
in this region is very low, with only one identical amino acid
(I154, SERT numbering) [3], and the presence of an α-
helical structure in IL1 of SERT is thus questionable.
Discussion
Homology modeling and docking
The homology modeling approach is a valuable tool for
investigating protein structures when experimental structures
arelacking.Homologymodelsareusefulforpredictingligand
potency and specificity through the use of different docking
approaches, and high-quality homology models have also
been used in the study of conformational changes using MD
simulations [38]. In the present study, 5-HT and ten other
tryptamine derivatives (SERT substrates) and the SSRI (S)-
citalopram were docked into the putative substrate binding
site of a SERT homology model, and possible conforma-
tional changes of SERT upon ligand binding were studied by
MD simulations.
The accuracy of homology models depends on three
factors: the sequence identity and functional similarity
between the template and target proteins; the amino acid
sequence alignments between the template and the targets;
and the resolution at which the crystal structure of the
template protein was resolved. For membrane proteins in
general, sequence identities between template and target
proteins of 50% have been found to yield membrane
homology models with a Cα-RMSD of approximately 1 Å
from the template structure in the transmembrane regions,
assuming that the template structure has been solved at a
resolution of 3.5 Å or better [39]. Sequence identities of
30% or more are, for most membrane proteins, predicted to
yield acceptable homology models with a Cα-RMSD of
approximately 2 Å in the TM regions [39].
The sequence identity between LeuT and SERT is approx-
imately 50% in the putative substrate binding site detected by
the ICM PocketFinder. In contrast, the overall sequence
identity between the transporters is less than 20%, but it rises
to approximately 35% in TMs that are predicted to be directly
involved in substrate binding (i.e., TMs 1, 3, 6 and 8). LeuT is
considered a good template for generating homology
models of SERT that can be used for ligand docking and
molecular dynamics. Actually, due to the topological
restrictions provided by the hydrophobic membrane
environment surroundings, membrane proteins such as
SERT actually have more limited ways of folding than
water-soluble proteins, which may suggest that mem-
brane protein homology models are more accurate than
homology models of water-soluble proteins at the same
level of sequence identity [39]. This also thus supports the
generation of acceptable homology models of not only the
SERT substrate binding site but the whole structure using
LeuT as a template.
Table 2 Atomic distances [Å] between amino acids that were proposed to play a role in the opening of a vestibule from the SERT substrate
binding site to the cytoplasm. Locations of amino acids are shown in parentheses
Distance [location] Initial SERT SERT (no ligand) SERT–5-HT
A SERT–5-HT
B SERT–(S)-citalopram
A SERT–(S)-citalopram
B
E78–R144 [N-terminus:
TM2/IL1]
7.0 9.3 13.7 1.9 14.6 6.3
R79–D452 [N-terminus: TM8] 1.7 1.7 1.7 6.1 1.8 8.2
R152–E453 [IL1–TM8] 1.7 4.3 1.8 9.0 3.0 2.0
R152–E508 [IL1–TM10] 17.2 11.5 8.6 2.7 11.4 14.7
E136–G340 [TM2–TM6] 1.8 2.7 1.8 1.9 2.1 1.9
E444–R462 [TM8–TM9] 6.6 1.7 1.7 1.7 1.7 1.8
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and the other tryptamine derivatives may bind in SERT:
the SERT–5-HT
A and SERT–5-HT
B binding modes
(Fig. 1). In both of these binding modes, the positively
charged amine moiety of 5-HT was in the vicinity of the
negatively charged D98 side chain, and the C6 position of
the indole ring was located close to A173 at the other end
of the molecule; however, the indole nitrogen moiety
pointed in different directions in the two binding modes.
Interestingly, similar binding modes of 5-HT to the SERT–
5-HT
A and SERT–5-HT
B binding modes have also been
obtained through docking and experimental studies by
other groups [10, 12, 35]. Celik et al. [10] found that the
C5 and C7 positions of 5-HT should be located in
hydrophilic and hydrophobic pockets of SERT, and
that the 5 hydroxyl moiety of 5-HT was in the vicinity
of T439 (TM8) [10]. Though the C5 and C7 moieties of
5-HT in both the SERT–5-HT
A and SERT–5-HT
B binding
modes described here are located in such regions, only
the localization of C5 of 5-HT in the SERT–5-HT
A
binding mode was found in the vicinity of T439. In
another study, however, 5-HT in a similar binding mode
to the SERT–5-HT
B binding mode showed good correla-
tion with experimental data and was also found to best
describe the cross-species sensitivities reported in sup-
port vector machine (SVM) sensitivity maps generated
for the human and Drosophila melanogaster serotonin
transporters [12]. This binding mode was also suggested
by Jørgensen et al. [35].
Our results show that the size of the putative substrate
binding site detected in this structure of SERTwas relatively
small and not optimal for the docking of larger compounds
suchas(S)-citalopram. Nonetheless, the binding mode of (S)-
citalopram has recently been studied by docking into
occluded SERT homology models and by experimental
site-directed mutagenesis [18]. Andersen et al. [18]f o u n d
that the fluorophenyl moiety of (S)-citalopram was located
near I172, A173 and N177, whereas the cyanophthalane
moiety was in proximity to V343. Though the cyanoph-
thalane moiety of (S)-citalopram in both binding modes in
the present study was in the vicinity of V343, only the
fluorophenyl of (S)-citalopram in the SERT–(S)-citalo-
pram
A binding mode was in the vicinity of I172 (Fig. 1). A
similar (S)-citalopram binding mode to the SERT–(S)-
citalopram
A b i n d i n gm o d eh a sa l s ob e e nu s e da si n i t i a l
binding mode in another MD study in SERT [35].
Our docking indicated that the tryptamine derivatives do
not interact with SERT in the aromatic subpocket of the
binding pocket, whereas (S)-citalopram does. A possible
mechanism of action of inhibition by (S)-citalopram may
therefore be that (S)-citalopram interferes with the closure
of the extracellular gating residues Y176 and F335,
stabilizing SERT in an outward-facing conformation,
thereby hindering conformational changes needed for
transport to occur. A similar mechanism of inhibition has
recently been suggested for TCAs [40].
Molecular dynamics simulations
In order to gain insights into SERT conformational changes
that may take place upon ligand binding, one representative
ligand orientation from each of the two possible binding
modes of 5-HT (representing the tryptamine derivatives)
and (S)-citalopram, as well as the apo-SERT structure, were
selected for MD simulations in POPC lipid bilayers. The
simulations were run for 22 ns (SERT–5-HT
A), 49 ns
(SERT–5-HT
B), 32 ns (SERT–(S)-citalopram
A), 23 ns
(SERT–(S)-citalopram
B) and 25 ns (apo-SERT), and aver-
age structures of each of the five MD simulations were
generated and used to analyze the results. Average
structures may represent unphysical states of SERT that
may not exist. However, the present average structures were
based on the last 10 ns of the MD simulation, where
energetically favorable and structural stable SERT–(ligand)–
POPC complexes were obtained. The average structures
used were thus considered to be representative of the
most densely populated conformations during this period
of the simulation.
The substrate 5-HT is expected to cause a different
conformational change of SERT than inhibitors such as (S)-
citalopram, as the former compound is transported whereas
the latter inhibits transport. In order to visualize such
conformational changes, the ICM PocketFinder was used to
detect pockets in the five average structures. In the average
structure from SERT-5HT
B binding mode simulation, the
pockets detected showed that a vestibule had started to
emerge that extended from the putative substrate binding
site towards the cytoplasm (Fig. 2). The results suggested
that the continued rearrangement of the unwound regions of
TM6, TM8 and IL1 relative to one another may open a
pathway from the substrate binding site to the cytoplasm
(Fig. 3). A similar vestibule was not observed in any of the
other simulations (results not shown).
A pocket extending from the cytoplasm up towards the
substrate binding pocket was formed during the MD
simulation of the SERT–5-HT
B complex. A corresponding
pocket was not formed during MD of the SERT–5-HT
A
complex. Based on these observations, we also examined
whether the position of 5-HT changed during the simulation
of the SERT–5-HT
B complex. By superimposing the initial
structure of SERT on the average SERT–5-HT
B structure
(12–21 ns), we found that the 5-HT hydroxyl group was
located closer to the Y95 (TM1) hydroxyl group at the
cytoplasmic end of the binding pocket in the average
SERT–5-HT
B structure. In addition, the atomic distance
between Y95 (TM1) and G338 (TM6) was slightly
1082 J Mol Model (2012) 18:1073–1085increased (Fig. 4). Prolonging the MD simulation up to
49 ns showed that these distances were maintained between
21 and 49 ns of MD simulation, and additional changes in
SERT structure or in 5-HT position were not seen.
The hydroxyl group of Y95 (TM1) and the backbone
oxygen atom of G338 in the unwound region of TM6 were
within hydrogen-bonding distance in the initial structure of
SERT, and this interaction might play a role in keeping the
translocation pathway closed. Our results thus suggest that
one of the first steps in 5-HT translocation is the formation
of a hydrogen bond between the 5-OH of 5-HT and Y95
(TM1), which may sever the hydrogen bond between
Y 9 5( T M 1 )a n dG 3 3 8( T M 6 ) .I na n o t h e rs t u d y ,t h e
mutation of G338 to cysteine (G338C) was shown to
stabilize SERT in an outward-facing conformation [33].
The transport activity of the G338C mutant was less than
5% of the wild-type transport activity; however, transport
could partially be restored by simultaneously mutating
Y95 to phenylalanine (Y95F), which indicates that Y95
(TM1)andG338(TM6)cannotbehydrogenbondedfor5-HT
transport to occur [33].
The amino acids in TM6 that separated the putative
substrate binding site from the cytoplasmic vestibule were
located in the unwound region of TM6, which in the initial
SERT structure consisted of G338, P339, G340, F341 and
G342, but in the average SERT–5-HT
B structure also
contained two more amino acids, S336 and L337. The
unwinding of the latter amino acids is in agreement with a
study suggesting that amino acids 334–337 in SERT are in
an unwound region based on aqueous accessibility data
[33]. This region contains several glycine residues [3] and
is thus expected to be very flexible: one study shows that
even the conservative mutations of G338 and G342 to
alanine (G338A and G342A, respectively) cause reductions
in 5-HT transport of approximately 28% and 10%,
respectively, as compared to the wild type [33].
The transmembrane helix closest to TM6 in the model was
TM2. Thus, an interaction between the unwound region of
TM6 and amino acids in TM2 might contribute to opening up
the binding site towards the intracellular region by pulling the
flexible unwound part of TM6 towards TM2. We observed
that a hydrogen bond was present between the backbone of
G340 (unwound region of TM6) and the side chain of E136
(TM2), as in LeuT [4]. Our results show that the distance
between the backbone nitrogen of G340 and the E136 side
chain did not change significantly during the MD simulation
of the SERT–5-HT
B complex (Table 2); however, super-
imposing the average structure on the initial SERT
structure showed that the G340 backbone nitrogen atom
and the E136 carboxyl carbon atoms shifted 2.5 Å during
the simulation (results not shown). Hence, though the
distance between G340 and E136 remains constant
during the MD simulation, the unwound TM6 region
and TM2 had moved 2.5 Å in the same direction, away
from the putative substrate binding site. An ionic
interaction between another TM2 amino acid, R144,
and E78 in the N-terminus also formed, and may have
contributed to the joint movement of TMs 2 and 6. E136
(TM2) is conserved among the Na
+-dependent NSS
transporters [3], and has been shown to be very important
for transport in SERT: a conservative mutation of this
glutamic acid to aspartic acid (E136D) causes a reduction
in SERT transport, and mutations to alanine or glutamine
(E136A, E136Q) inhibit transport [41]. The atomic
distance between R144 (TM2) and E78 (N-terminus)
decreased from 7 Å in the initial structure of SERT to
1.9 Å in the average structure of SERT–5-HT
B (Table 2).
In TM8, three amino acids were found to be particularly
interesting with respect to opening an intracellular vestibule
from the putative substrate binding site to the cytoplasm:
namely E444, D452 and E453. E444 (TM8) was located in
close proximity to the substrate binding site, and during all
MD simulations an ionic interaction between E444 (TM8)
and R462 (TM9) was formed (Table 2). D452 and E453
were located at the cytoplasmic end of the TM8. During the
MD simulation of the SERT–5-HT
B complex, we observed
that the distance between E453 (TM8) and R152 (IL1)
increased whereas the distance between D452 (TM8) and
K153 (IL1) decreased, thus changing the conformation of
this long loop. The importance of R152 for transport is in
agreement with a recent study in mouse SERT showing that
the G39/K152 phenotype has reduced transport in compar-
ison with the wild type (E39/R152 phenotype) [42].
Very interestingly, we observed that during the MD
simulation of SERT–5-HT
B, an interaction between R152
(IL1) and E508 (TM10) developed. In the initial structure
of SERT, the atomic distance between these residues was
>17 Å, while the distance decreased to only 2.7 Å in the
average SERT–5-HT
B structure (Table 2). Furthermore,
this interaction was not formed in any of the other MD
simulations (Table 2). E508 is one of a few amino acids
in TM10 that are fully conserved between SERT and
LeuT [3]. Interestingly, E508 (TM10) was also located in
the region of E136 (TM2) in SERT, and it is suggested
that this amino acid interacts with G340 in the unwound
region of TM6 (see above); it is also known to be
important for transport in SERT [41].
Summary
Our MD simulations indicate that the SERT–5-HT
B binding
mode and not the SERT–5-HT
A binding mode induces
conformational changes in SERT that may be associated
with substrate translocation. The simulations suggest that
substrate translocation may involve forming and breaking
ionic interactions between TM6, TM8 and IL1 and their
J Mol Model (2012) 18:1073–1085 1083interaction partners. Although our observations are in
agreement with experimental studies, the suggested mech-
anism is hypothetical, as it is based solely upon theoretical
calculations using a homology-based model.
The simulations may indicate that the formation of a
hydrogen bond between Y95 in TM1 and 5-HT causes a
hydrogen bond between Y95 and G338 in TM6 to be broken,
enabling the unwound region of TM6 to move away from the
substrate binding site and transport to begin. The
formation of an ionic interaction between R144 (TM2) and
E78 (N-terminus) and the interaction between G340
(unwound region of TM6) and E136 (TM2) then cause TM6
to move away from the putative substrate binding site. The
movements of E136 (TM2) also affect the nearby amino acid
E508 (TM10), causing it to interact with R152 in IL1, thus
changing the conformation of this loop. Simultaneously, an
ionic interaction between E444 (TM8) and R462 (TM9),
located close to the putative substrate binding site, is formed.
The interaction between E453 in the cytoplasmic part of TM8
and R596 in TM12 may also contribute to relocating TM8
awayfromthe vestibule. The formation ofanionic interaction
between E78 in the N-terminus and R144 in TM2, and the
subsequent movement of TM2, may also weaken the
interaction between the N-terminus and TM8, as illustrated
by the increase in the R79–D452 distance (Table 2).
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